Background
==========

Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor arising from the parafollicular cells of the thyroid gland and approximately 75% of cases are sporadic type (SMTC) \[[@B1]\]. Survival rate is closely related to clinical parameters such as tumor stage, age of diagnosis, elevated postoperative serum calcitonin (CT) levels, and recurrence of the tumor \[[@B2]\]. Other parameters that contribute to survival rates include lymph node metastasis, tumor size \>4 cm, extrathyroid and extranodal tumor extensions \[[@B3]\]. Thus, patients who are treated in the earlier stages of the disease have a better prognosis. Patients with tumors that are limited to the thyroid (stage I) have a survival rate of 95% at 10 and 20 years. Patients with advanced tumors, stages III and IV, have a survival rate of 55% and 28% at 10 and 20 years, respectively. Frequently, persistence of the disease is associated with elevated postoperative serum CT levels and persistence of the tumor increased over time. However, 30% of SMTC patients continued to show only elevated CT levels without additional clinical evidence of the disease (persistence), even after 15 years \[[@B2],[@B3]\].

At genetic level, the first event in SMTC tumorigenesis is thought to be the M918T *RET* mutation (ATG → ACG) \[[@B4]-[@B11]\]. This mutation is associated with 30--66% of SMTC and 95% of Multiple Endocrine Neoplasia type 2B \[[@B4]-[@B9]\]. This mutation has been associated with a poor prognosis, tumor recurrence and the presence of lymph node metastases \[[@B10]-[@B13]\].

Comparative genomic hybridization (CGH) studies have been widely applied to cancer research \[[@B14],[@B15]\]. CGH analysis has been performed in SMTCs showing common chromosomal alterations as loss in 1p, 3q, 4q, 13q, 17, 22q and gains in 11q, 12p, 14q, 19q and 22q (Table [1](#T1){ref-type="table"}). Some of these imbalances have been related to specific clinical behavior such as the clinical outcome \[[@B16]\].

###### 

Chromosomal alterations reported in carcinoma tissues from SMTC using CGH analysis

  **Tissue**           **n**   **Ret mut**   **Gains**                                                **Losses**                                                                                        **Reference**
  -------------------- ------- ------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------- --------------------------------
  SMTC primary tumor   10      Unknown       1q, 6, 7p, 11q, 21q                                      1p, 3q, 3, **13**, 18p, 18q, **22**                                                               Hemmer et al., 1999 \[[@B18]\]
  SMTC primary tumor   9       M918T         1p, 5p, 7q, 8q, 9q, **11q**, 16, 19p, **19q**, **22q**   **1p**, 2q, 3q, 3, 4q, 9p + q, 10, 12p, 12q, **13q**.                                             Frisk et al., 2001 \[[@B16]\]
  SMTC primary tumor   12      M918T         6p, 6, 7, **12p**, **14q,** 15q, 16, **19**, X           **1p**, 3q, **3**, **4q**, 5q, 9, 11, **13q**, 16p,16, 17p, **17**, 19, 20q, 20, **22q**, **X**   Marsh et al., 2003 \[[@B19]\]
  SMTC primary tumor   1       M918T         18p                                                      6p , 16p                                                                                          Present case
  SMTC metastasis      1       M918T         6 ,14q                                                   X                                                                                                 Marsh et al., 2003 \[[@B19]\]
  SMTC metastasis      1       M918T         2q, 3q, 4p + q, 5p + q, 6q, 8q, 12p + q, 13q, Xq         1p, 1q, 6p, 8p, 8q, 9q, 10p, 10q, 11q, 12q, 15q, 16, 17, 19, 20, and 22q                          Present case

Note: n: number of cases studied; Ret mut: type of RET mutation; M918T: codon 918 (Met-- \> Thr). In bold letter the most common CGH gains and losses. Bold font indicates most common CGH imbalances reported by author.

In order to know which chromosomal imbalances occur in a primary SMTC harboring a M918T RET mutation and its lymph node metastasis in a patient with 15 years of clinical follow-up, a CGH analysis was performed.

Case presentation
=================

In this study, we report a case of a 70 year-old female who was diagnosed with SMTC 15 years ago. A total resection of the thyroid gland and a resection of the right lymph nodes in the neck were performed at age 55. At the time of surgery, a unilateral tumor was detected in the right lobe of the thyroid. Histopathological findings confirmed a 7.5x3.5x2cm tumor (T2) with extraglandular extension, 8/17 positive lymph nodes metastases (N1b) and no distant metastases (M0) were found. According to TNM classification, this patient was diagnosed as MTC stage III. One year later, the patient presented with persistently high serum CT levels (2,400 pg/mL). During a second surgery, a left lymph nodes resection was performed and histopathological analysis confirmed the presence of several lymph node metastases (10/49). At present, the patient is alive and has persistent disease, confirmed by periodical elevated serum CT levels (3,193 pg/mL at the latest screening).

Molecular diagnostic testing confirmed the presence of the M918T RET mutation in the tumor and lymph node metastases previously. Interestingly, our case study demonstrate that despite the mutation and the presence of several lymph nodes metastases, the patient experienced a good survival rate (15 years after surgery) and still alive. Then, we focused in search of genetic DNA alterations by CGH that could be important in the favorable prognosis of this patient. The CGH procedure was performed using reagents and kits from Vysis Inc. (Downers Grove, IL), following the manufacturer's instructions. Tumoral DNA was labeled using the CGH nick translation kit and the hybridization mixture was prepared according to the CGH reagent kit, consisting of 200 ng of spectrum-green labeled tumoral DNA, 200 ng of spectrum-red labeled normal male reference DNA and 20 μg of human Cot-1 DNA. Hybridization was performed over 3 days at 37 °C on normal male metaphase spreads (Vysis, Downers Grove, IL). Digital images were collected using the Smart Capture (Vysis) software with a charged coupled device camera mounted on an epifluorescence microscope. In the primary tumor, the chromosomal alterations detected were losses in 6p and 16p and gain in 18p, while 25 chromosomal alterations were detected in the lymph node metastasis with more losses than gains (Table [1](#T1){ref-type="table"}).

Discussion
==========

Cancer progression and the metastasis result from the accumulation of multiple genetic changes. In the current study, DNA from a primary tumor and a lymph node metastasis of a persistent SMTC patient, harboring the M918T RET mutation, was subjected to CGH analysis to evaluate additional genetic changes. This analysis demonstrated differences in genetic changes between the primary tumor and the metastasis, 3 genetic changes vs. 25 genetic changes, respectively. Interestingly, DNA losses were more common than gains, and a complete deletion of chromosomes 16, 17, 19, and 20 were observed in the metastasis (Figure [1](#F1){ref-type="fig"}). In contrast, a high number of chromosomal alterations in lymph nodes metastasis have been previously found \[[@B16]\]. These findings could indicate a complex pattern of DNA alterations related to metastasis in this patient. It is important to note that the chromosomal alterations observed in the primary tumor are also present in its metastasis, indicating that those changes could be associated to clonal origin. This is also supported by the presence of the M918T RET mutation in the metastasis.

![**CGH analysis profile from SMTC tissues: A) Primary tumor, B) Metastasis.** Red lines to the left of chromosomes represent losses (CGH fluorescence ratios \<0.80), green lines to the right of chromosomes represent gains (ratio \>1.20). Abbreviations: LR-T: Primary tumor, LR-M: Metastasis.](1746-1596-7-63-1){#F1}

To date, only few studies have analyzed chromosomal imbalances in primary tissue of SMTC \[[@B16]-[@B18]\]. Our data support previous results indicating that the SMTC could be characterized by more DNA losses than gains \[[@B16],[@B18]\]. One report had suggested that the SMTC harboring the M918T RET mutation have a higher degree of chromosomal instability and usually display a higher number of DNA alterations \[[@B16]\]. However, the fewer number of DNA alterations present in the primary tumor of our patient could be related to persistence or good prognosis. If this is true, the low number of specific DNA alterations in the primary tumor could be of prognostic value in SMTC patients.

In other study, the loss of chromosomes 1p, 3q 13q and 22q were detected in some SMTC patients with M918T RET mutation. However, the chromosomal alterations in the metastasis described in the present study, are partially similar than those described for the primary tumor in other reports (Table [1](#T1){ref-type="table"}). Therefore, it is possible that some of these DNA alterations could be associated with clinical parameters such as prognosis, tumor size, and metastasis. For instance, gains of chromosome 19 and chromosome 11q12 were observed in patients whom died of the disease, and they also harbored the M918T mutation \[[@B16]\]. It is clear that heterogeneity in chromosomal alterations is present in SMTCs. Several authors have suggested that these CGH imbalances could contribute to outcome or prognosis and that those genetic regions may contain genes associated to the development of SMTC \[[@B16]-[@B19]\]. An overexpression of genes involved in proliferation and invasion such as PTN (7q33); ESM1 (5q11), and CEACAM (19q13) could also characterize an aggressive SMTC \[[@B20]\]. Thus, our results are supported by these previous findings indicating that chromosomal changes at 6p, 16p and 18p observed in the SMTC, could not be associated with an aggressive prognosis. On the other hand, it is widely known that the M918T RET mutation is associated with poor prognosis and persistence of the disease \[[@B9]-[@B12]\]. According to our results, the patient harboring the M918T RET mutation failed in the poor prognosis, however, she had persistence SMTC. In this case we hypothesized that our patient harboring the RET mutation (aggressive mutation) could be subjected to an epigenetic mechanism as methylation (for instance, an imprinted mutated allele) allowing the long survival (good prognosis). Based on our results, we suggest that: 6p, 16p, and 18p regions could contain genes associated to cancer that are common in human cancer genome \[[@B21],[@B22]\] and the loss or gain could be associated to good prognosis and long-term survival. More detailed analyses are needed to support the existence of good prognostic markers in chromosomal regions that contain imbalances. To avoid a limited significance about genetic alterations in persistence SMTC harboring M918T RET mutation patients should be necessary to analyze more of these kind of patients.

Conclusion
==========

In summary, the chromosomal alterations in SMTC are quite heterogeneous; however, the number and specific DNA alterations could mark our patient's prognosis even when harbors the M918T RET mutation. Losses in 6p and 16p, and gain in 18p could be related to a favorable prognostic outcome, persist disease and high serum CT levels in SMTC.
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